Results 151 to 160 of about 91,755 (270)

A phase IIa study of the anti‐PD‐L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL‐T trial

open access: yesBritish Journal of Haematology, EarlyView.
The AVAIL‐T study, the first evaluation of programmed death ligand 1 (PD‐L1) blockade in relapsed/refractory peripheral T‐cell lymphomas (PTCL), demonstrated limited single agent activity with durable responses seen in a minority. Circulating tumour DNA revealed distinct mutational dynamics and mass cytometry identified perturbed T‐cell subsets ...
Matthew J. Ahearne   +28 more
wiley   +1 more source

Prospective phase I study of nivolumab to promote graft‐versus‐tumour in relapsed or refractory haematological malignancy post allogeneic haematopoietic stem cell transplantation

open access: yesBritish Journal of Haematology, EarlyView.
Baseline immunophenotype and gene expression predict suitability for salvage nivolumab in patients with relapsed/refractory haematological malignancy. Summary Allogeneic haematopoietic stem cell transplantation (alloHSCT) relies on donor‐derived T cells to mediate the graft‐versus‐tumour (GVT) effect, but relapse may result from impaired immune ...
Trung Q. Ngo   +7 more
wiley   +1 more source

The impact of programmed death ligand 1 expression on prognosis in penile cancer: a systematic review and meta‐analysis

open access: yesBJU International, EarlyView.
Objectives To determine the prevalence of programmed death ligand 1 (PD‐L1) expression in penile squamous cell carcinoma (PSCC) and evaluate its associations with clinicopathological features and survival outcomes. Patients and Methods A systematic review was carried out using PubMed, the Excerpta Medica dataBASE (EMBASE), Scopus, Web of Science and ...
Diarmuid D. Sugrue   +5 more
wiley   +1 more source

Circumscribed Meningeal Melanocytic Neoplasms: CNS WHO Grade, Molecular Profile, and Clinical Outcomes

open access: yesBrain Pathology, EarlyView.
In this study including 31 circumscribed meningeal melanocytic neoplasms (melanocytoma, intermediate‐grade melanocytic tumor [IMT], and melanoma), overall survival (OS) differed significantly among the groups, with melanoma showing significantly worse OS than melanocytoma and IMT showing intermediate OS between melanocytoma and melanoma.
Yi Zhu   +12 more
wiley   +1 more source

Low-Dose Nivolumab in Various Cancers: A Real-World Exploratory Analysis in Resource-Constrained Settings. [PDF]

open access: yesCancer Rep (Hoboken)
Pandit S   +7 more
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

open access: yesBritish Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu   +6 more
wiley   +1 more source

Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio‐oncology Registry

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, offering improvements in survival across various malignancies. However, their toxicities pose a major challenge for cardio‐oncology units. Despite their growing importance, data on effectiveness of such specialized units in mitigating ICI‐associated ...
Elias Haj‐Yehia   +6 more
wiley   +1 more source

Tinostamustine-nivolumab therapy is associated with antigen-specific cellular and humoral immune responses in heavily pre-treated patients with advanced melanoma. [PDF]

open access: yesCancer Immunol Immunother
Mane S   +15 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy